Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Celecoxib may stop the growth of cancer by stopping blood flow to the tumor.
Erlotinib and celecoxib may stop the growth of tumor cells by blocking the enzymes necessary
for their growth. Combining celecoxib with erlotinib may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of celecoxib when
given together with erlotinib in treating patients with stage IIIB or stage IV non-small cell
lung cancer.